Following re-scheduling, will state-regulated cannabis companies face FDA regulation similar to pharmaceutical companies? 

Re-scheduling wouldn’t alter FDA’s authority over cannabis or state-regulated companies. Just as there are GMP rules for food, if a company sells a cannabis edible across state lines, it’s bound by GMP rules, whether cannabis is scheduled or not. FDA generally hasn’t enforced these rules on cannabis-containing products (except approved drugs).

FDA maintains an FAQ regarding states allowing cannabis for medical use without FDA approval. It emphasizes the need for clinical trials to ensure cannabis product safety and efficacy. FDA offers support and information on federal and scientific standards for states considering medical research on cannabis and derivatives.